A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants with Non-Segmental Vitiligo.
This research study is looking into a new medication called MK-6194 for adults who have non-segmental vitiligo. This type of vitiligo causes white patches on the skin. The study is divided into groups, where some participants will receive the new medicine and others will receive a 'dummy' medicine (placebo) – neither they nor the doctors will know who is getting what. The main goal is to find out if MK-6194 can reduce the size of white patches on the face after 24 weeks. Researchers will also be carefully checking for any side effects and seeing how many people need to stop taking the medicine because of these effects. A secondary goal is to see if it helps with white patches on the body. This is an early-stage study to learn more about the medicine’s effects.
De un vistazo
¿De qué trata este estudio?
This study is a clinical trial, which means it's a careful medical research study involving people. The purpose of this specific trial is to test a new medicine, called MK-6194, for adults who have a skin condition called non-segmental vitiligo. If you have vitiligo, your body's immune system mistakenly attacks the cells that give your skin its colour (melanin), leading to white patches on your skin.
Researchers want to see if MK-6194 can help to bring back colour to the white patches on the face and other body areas. They also want to understand if the medicine is safe to use and what side effects it might cause. To do this, some people in the study will get the new medicine, while others will get a 'placebo' – which looks like the medicine but has no active ingredients. This helps researchers compare the effects accurately. Neither you nor your study doctor will know which one you are getting, to keep the results fair and unbiased.
This is an early-stage study (Phase 2). This means it's one of the first times this medicine is being tested in a larger group of people with vitiligo. The information gathered from this study will help decide if the medicine is promising enough to move on to bigger studies, and eventually, whether it could become a new treatment option for vitiligo.
Puntos clave
- Tests a new medicine (MK-6194) for non-segmental vitiligo.
- Compares the new medicine to a dummy medicine (placebo).
- Focuses on reducing white patches on the face and checking safety.
- It's an early-stage study to learn more about the medicine.
- Participants will be adults, aged 18 and over.
¿Quién puede ser elegible?
To be able to join this study, you need to be an adult, aged 18 years or older. There is no upper age limit for taking part.
Both men and women can join this study if they meet the other requirements. The study doctors will carefully check your health and your specific type of vitiligo to make sure the study is a good fit for you.
They will make sure that taking part is safe for you and that the results from your participation will be helpful for understanding the new medicine.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- ¿Tienes 18 años o más?
- Do you have non-segmental vitiligo?
- ¿Está dispuesto a asistir a visitas regulares a la clínica?
- Are you comfortable with the possibility of receiving a placebo?
- Are you willing to follow all study instructions carefully?
¿En qué consiste la participación?
If you decide to take part in this study, you'll be assigned to receive either the new medicine, MK-6194, or a placebo (a dummy medicine). You won't know which one you're getting, and neither will your study doctor, to ensure fair results. You'll need to attend a series of regular visits at the study clinic over a period of 24 weeks. During these visits, doctors and nurses will monitor your health, evaluate your vitiligo, and check for any side effects.
Assessments will include looking at your skin, especially on your face, to measure any changes in the white patches. You'll also likely have blood tests and physical examinations. After the 24 weeks of treatment, there will be further follow-up visits to continue monitoring your health for a period. The total duration of your involvement in the study, including treatment and follow-up, will be explained in detail by the study team.
Riesgos y beneficios potenciales
Ubicaciones (5)
- —No verificadoBélgica
- —No verificadoAlemania
- —No verificadoEspaña
- —No verificadoFrancia
- —No verificadoPaíses Bajos
Preguntas comunes
What is 'non-segmental vitiligo'?
Non-segmental vitiligo is a common type of vitiligo where white patches can appear on various parts of the body, often symmetrically, meaning roughy the same on both sides.
What does 'placebo-controlled' mean?
It means some people get the new medicine, and others get a 'dummy' medicine (placebo) that looks the same but has no active drug. This helps us compare the real effects of the medicine.
What is a 'Phase 2a' study?
This is an early stage of research. It means the medicine has been tested for safety in a small group, and now researchers are looking at how well it works and its safety in a slightly larger group of people with the condition.
¿Sabré si estoy recibiendo el medicamento real o el placebo?
No, both you and the study doctors will not know. This is called 'double-blind' and ensures the study results are as fair and accurate as possible.
¿Cuánto tiempo durará el estudio para mí?
The treatment part of the study lasts 24 weeks. After that, there will be follow-up visits, so your total time in the study will be longer than 24 weeks, and the study team will explain the full duration.
Cómo obtener más información
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
¿Interesado en participar?
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.